Other · developed by Genmab
GEN3018 is an agent given by intravenous infusion. It is studied in relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07384715 | Phase 1 | R/R AML | Recruiting | GMAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaHigher-Risk Myelodysplastic SyndromeR/R AMLR/R HR-MDS
Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →